Acadia Pharmaceuticals (ACAD)

Company Description

ACADIA Pharmaceuticals (ACAD) focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. Its lead drug candidate is NUPLAZID, which has delivered positive data in Phase III pivotal trials with a pristine safety profile for the treatment of Parkinson’s disease psychosis, an unmet medical need.   The potential blockbuster is also in Phase II development for Alzheimer’s disease psychosis and is currently planning a Phase II trial for the treatment of schizophrenia. ACAD also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc.


3611 Valley Centre Drive; Suite 300
San Diego, CA 92130
United States

(858) 558-2871


Get BioInvest's perspective on Acadia's CEO

Latest Company News